Edy Ippolito1, Alessandra Guido2, Gabriella Macchia3, Francesco Deodato3, Lucia Giaccherini4, Andrea Farioli5, Alessandra Arcelli4, Dajana Cuicchi5, Leonardo Frazzoni5, Savino Cilla6, Milly Buwenge4, Giovanna Mantini7, Anna R Alitto7, Marianna Nuzzo3, Vincenzo Valentini7, Marcello Ingrosso8, Alessio G Morganti4, Lorenzo Fuccio5. 1. Radiotherapy Unit, Campus Bio-Medico University, Rome, Italy. 2. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine DIMES, University of Bologna, Bologna, Italy alessandraguido2008@gmail.com. 3. Radiotherapy Unit, Giovanni Paolo II Research and Care Foundation, Campobasso, Italy. 4. Radiation Oncology Center, Department of Experimental, Diagnostic and Specialty Medicine DIMES, University of Bologna, Bologna, Italy. 5. Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy. 6. Medical Physics Unit, Giovanni Paolo II Research and Care Foundation, Campobasso, Italy. 7. Department of Radiotherapy, A. Gemelli Hospital, Sacred Heart Catholic University, Rome, Italy. 8. Endoscopy Unit, Giovanni Paolo II Research and Care Foundation, Campobasso, Italy.
Abstract
BACKGROUND/AIM: The Vienna Rectoscopy Score (VRS; from 0, absence of rectal mucosal changes, to 5) assessed 1 year after radiotherapy is a surrogate end-point of late rectal toxicity. The aim of this study was to investigate the association between treatment-related factors and 1-year VRS. PATIENTS AND METHODS: We performed a retrospective analysis of prospectively collected data. Patients with prostate adenocarcinoma treated with definitive or postoperative radiotherapy (RT) underwent endoscopy 1 year after RT. Relationships between VRS of 2 or more and treatment parameters were investigated by univariate and multivariate logistic analyses. RESULTS: One hundred and ninety-five patients (mean age=69 years; range=43-81 years) were considered eligible for the study. At univariate analysis, patients treated with hypofractionation plus radiosurgery boost (p<0.001) and an equivalent dose in 2 Gy per fraction (EQD2) (α/β=3) ≥75 Gy (p<0.001) was associated with a significantly higher incidence of VRS ≥2 after 1 year of follow-up. At multivariate analysis, radiosurgery boost was an independent risk factor for developing rectal mucosal lesions (VRS ≥2), yielding an odds ratio (OR) of 4.14 (95% confidence interval (CI)=1.2-13.8), while pelvic surgery was inversely associated with VRS ≥2 (OR=0.39; 95% CI=0.17-0.94). CONCLUSION: Hypofractionation followed by radiosurgery boost significantly increased the risk of developing late-onset rectal mucosal changes. Therefore, special care and preventative treatment strategies are needed when using radiosurgery boost after hypofractionated RT. Copyright
BACKGROUND/AIM: The Vienna Rectoscopy Score (VRS; from 0, absence of rectal mucosal changes, to 5) assessed 1 year after radiotherapy is a surrogate end-point of late rectal toxicity. The aim of this study was to investigate the association between treatment-related factors and 1-year VRS. PATIENTS AND METHODS: We performed a retrospective analysis of prospectively collected data. Patients with prostate adenocarcinoma treated with definitive or postoperative radiotherapy (RT) underwent endoscopy 1 year after RT. Relationships between VRS of 2 or more and treatment parameters were investigated by univariate and multivariate logistic analyses. RESULTS: One hundred and ninety-five patients (mean age=69 years; range=43-81 years) were considered eligible for the study. At univariate analysis, patients treated with hypofractionation plus radiosurgery boost (p<0.001) and an equivalent dose in 2 Gy per fraction (EQD2) (α/β=3) ≥75 Gy (p<0.001) was associated with a significantly higher incidence of VRS ≥2 after 1 year of follow-up. At multivariate analysis, radiosurgery boost was an independent risk factor for developing rectal mucosal lesions (VRS ≥2), yielding an odds ratio (OR) of 4.14 (95% confidence interval (CI)=1.2-13.8), while pelvic surgery was inversely associated with VRS ≥2 (OR=0.39; 95% CI=0.17-0.94). CONCLUSION: Hypofractionation followed by radiosurgery boost significantly increased the risk of developing late-onset rectal mucosal changes. Therefore, special care and preventative treatment strategies are needed when using radiosurgery boost after hypofractionated RT. Copyright
Authors: L Fuccio; A Guido; L Laterza; L H Eusebi; L Busutti; F Bunkheila; E Barbieri; F Bazzoli Journal: Aliment Pharmacol Ther Date: 2011-07-25 Impact factor: 8.171
Authors: Alan Pollack; Gail Walker; Eric M Horwitz; Robert Price; Steven Feigenberg; Andre A Konski; Radka Stoyanova; Benjamin Movsas; Richard E Greenberg; Robert G Uzzo; Charlie Ma; Mark K Buyyounouski Journal: J Clin Oncol Date: 2013-10-07 Impact factor: 44.544
Authors: Petra Georg; Christian Kirisits; Gregor Goldner; Wolfgang Dörr; Johann Hammer; Regina Pötzi; Daniel Berger; Johannes Dimopoulos; Dietmar Georg; Richard Pötter Journal: Radiother Oncol Date: 2009-02-23 Impact factor: 6.280
Authors: Anna Rita Alitto; Luca Tagliaferri; Valentina Lancellotta; Andrea D'Aviero; Antonio Piras; Vincenzo Frascino; Francesco Catucci; Bruno Fionda; Christian Staackmann; Simonetta Saldi; Vincenzo Valentini; Gyorgy Kovacs; Cynthia Aristei; Giovanna Mantini Journal: In Vivo Date: 2020 May-Jun Impact factor: 2.155